October 2, 2009 – Results from a multicenter study of Cheetah Medical's Exercise Cardiac Output (ECO) stress test protocol for chronic heart failure were published earlier this month in the Journal of Cardiac Failure, the official journal of the Heart Failure Society of America and the Japanese Heart Failure Society. With approximately 6 million Americans diagnosed with heart failure, it is a leading cause of morbidity and mortality. After heart failure is diagnosed, the one-year mortality rate is high, with one in five dying. Eighty percent of men and 70 percent of women 65 years of age who have heart failure will die within eight years, and one in eight U.S. deaths has HF mentioned on the death certificate. Unfortunately, heart failure specialists have limited tools with which to monitor heart failure progression, determine prognosis and response to treatment. Recently, it was shown that peak cardiac output and peak cardiac power output are the strongest predictors of heart failure severity, however access to these current methods is limited to a minute portion of heart failure patients due to cost and complexity of the devices. In this study, Cheetah Medical's NICOM system was used to continuously monitor the cardiac output response during exercise stress testing as well as cardiac power output and a host of other hemodynamic parameters in patients with varying degrees of chronic heart failure and compared to the traditional method of measuring oxygen consumption which are obtained from analysis of expired gases. The results from both methods correlated extremely well, demonstrating the potential to use the NICOM system to routinely monitor heart failure patients without the significant limitations of expired breath gas technologies. “We continually search for practical means of assessing the status of our heart failure patients that are useful both for routine clinical practice and for clinical research,” said Matthew Maurer, M.D., director of the clinical cardiovascular research laboratory for the elderly, associate professor of clinical medicine at Columbia University Medical Center and the study's primary investigator. “Although the usefulness of measuring oxygen consumption is well established, these data suggest that additional physiologic and prognostic information can be obtained using the NICOM, which is as easy to measure as an electrocardiogram and does not require special training for its interpretation." Daniel Burkhoff, M.D., Ph.D., is the medical director of Cheetah Medical, an adjunct associate professor of Medicine at Columbia University Medical School and a leading clinical researcher in the field of heart failure. "With the results of this study showing good correlations to oxygen consumption and several prior independent studies showing that peak cardiac power can be even more predictive of outcomes, we are encouraged that we will see these measurements used more often in a variety of settings,” Dr. Burkhoff said. “Currently, the NICOM appears to offer the simplest solution for clinicians to measure cardiac output and power during exercise. We are planning a large multicenter study to confirm the prior smaller studies to prove the utility of peak cardiac power for predicting the risks of hospitalizations, the need for heart transplant, left ventricular assist devices and mortality." For more information: www.cheetah-medical.com
News | October 02, 2009
Cardiac Function Measured During Stress With Cheetah's BIOREACTANCE Offers Insights Into Heart Failure
News | Heart Failure| October 20, 2017
Trial Data Show Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...